Bruker introduces new OmniScape workflows for de novo identification and proteoform characterization
Novel glycoproteomics de novo workflows with timsOmni™ and OmniScape™ enable confident proteoform characterization
14 Nov 2025
With OmniScape™ version 2026, Bruker introduces significant improvements for its proteomics de novo workflow. Notable advancements encompass the residue-specific score and visualization via a confidence sequence heatmap for results validation.
In addition, the unique advantage of electron-based activation (ECD, EXD, and EID) on the timsOmni™ has been demonstrated for comprehensive glycopeptide analysis. Extended glycan structures were preserved on the peptide backbone, allowing further investigation into biologically highly relevant glycopeptide topology through MSⁿ experiments.
The versatility of timsOmni™ enables scientists to precisely localize glycan moieties and gain detailed insights into PTMs, advancing both structural and functional understanding of biological networks.
Dr. Francisco Alberto Fernandez Lima, FIU, USA, said, “Our laboratory has extensively utilized OmniScape for de novo and top-down protein-PTM sequence validation from ExD and UVPD datasets from timsTOF and MRM-MS instruments. Different from alternative approaches, OmniScape is more user friendly and allows for interactive fragment assignment/confirmation of proteoforms including variable AA level PTMs, m/z internal calibration and MS-BLAST search for database inquiries.”